Sunday Poster Session
Edward V. Loftus, Jr., MD, FACG
Rochester, MN, United States
|Outcomea,b||n||Adalimumab (N=195)||n||Ustekinumab (N=191)|
|Change from baseline at Week 52|
|IBDQ score||192||43.0 (37.1)||186||50.0 (40.2)|
|Bowel symptoms score||193||13.3 (12.0)||188||16.1 (12.6)|
|Emotional function score||192||15.7 (14.5)||187||16.7 (15.9)|
|Systemic symptoms score||194||7.1 (6.6)||190||8.5 (7.1)|
|Social function score||194||7.4 (7.7)||189||8.7 (8.2)|
|Achievement of clinically meaningful improvement at Week 52|
|IBDQ score ≥16-point increase from baseline, n (%)||123 (63.1)||127 (66.5)|
|IBDQ remission,c n (%)||101 (51.8)||102 (53.4)|
a Patients who had a prohibited CD-related surgery, had prohibited concomitant medication changes, or discontinued study agent due to lack of efficacy or due to an adverse event indicated to be of worsening CD prior to the designated analysis time point had their baseline value carried forward for continuous endpoints or were considered not to have achieved the endpoint for binary endpoints.
b Patients who had insufficient data at the designated analysis time point had their last value carried forward for continuous endpoints or were considered not to have achieved the endpoint for binary endpoints.
c IBDQ remission = IBDQ score >170.